CERT logo

CERTARA INC

CERTNASDAQ
๐Ÿ† #2043 by market capEarnings Nov 5US Equity
$8.01โ–ผ $0.12 (โˆ’1.48%)
Live
1hโ–ฒ 0.1%
24hโ–ผ 1.5%
7dโ–ฒ 0.1%
14dโ–ผ 1.1%
30dโ–ฒ 18.1%
1yโ–ผ 25.5%
๐ŸฆMarket Cap
$1.25B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
+8.8%
Slowing
๐Ÿ“ŠGross Margin
58.3%
Healthy
๐Ÿ’ตFCF Margin
15.1%
Healthy
โš–๏ธP/S Ratio
3.1x
Fair
Otter Score
47
Weak

Trading Snapshot

Day Range
$7.90 โ€“ $8.12
52-Week Range
$4.45 โ€“ $13.88
Volume
$2.00B
Avg Volume
$2.24B
Shares Outstanding
155.6M
Next Earnings
Oct 14, 2026

Fundamentals Snapshot

Annual Revenue
$419M
Last Q Revenue
$93M
P/E Ratio
-18.3
P/S Ratio
3.1x
EPS (TTM)
$-0.44
Dividend Yield
0.00%

Why Investors Own CERT

  • โœ“High-growth profile โ€” revenue up +29.7% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 79% gross margin and 22% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$419Mโ–ฒ +24.7% YoY
Gross Margin (TTM)
78.7%โ–ฒ +1.7% YoY
Operating Income (TTM)
$104Mโ–ฒ +24.7% YoY
Free Cash Flow (TTM)
$90Mโ–ฒ +24.7% YoY

About CERTARA INC

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Weak
47/100

Analyst Ratings

โ“˜
Consensus
Buy
19 analysts
Strong Buy3
Buy7
Hold9
Sell0
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

Yahooยท5d ago

The Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Why

In early August 2026, Certara reported second-quarter results showing slightly higher sales of US$93.27 million but a much larger net loss of US$55.27 million, alongside executive reshuffling including the departure of President and Chief Commercial Officer Leif Pedersen and the appointment of Julien Perrier as Chief Commercial Officer and Eric Jahn as Chief Information Officer. At the same time, Certara reaffirmed its 2026 revenue outlook while expanding its share repurchase authorization...

๐Ÿ›ฐ๏ธ
Benzingaยท7d ago

Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5

Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $6.5 to $7.5.

Yahooยท7d ago

Certara (CERT) Q2 2026 Earnings Call Transcript

Software revenue hit 53% of total as AI-assisted code boosted development 65% year over year.

Yahooยท7d ago

Certara, Inc. Q2 2026 Earnings Call Summary

Moby summary of Certara, Inc.'s Q2 2026 earnings call

SeekingAlphaยท7d ago

Certara, Inc. 2026 Q2 - Results - Earnings Call Presentation

2026-08-04. The following slide deck was published by Certara, Inc.

SeekingAlphaยท7d ago

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript

Certara, Inc. (CERT) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsJon Resnick - CEO & DirectorFaiz Mohammed - Interim CFO, Senior...